ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer

Koca, E; Niravath, PA; Ensor, J; Patel, TA; Li, XX; Hemati, P; Wong, HL; Qian, W; Boone, T; Zhao, J; Ramshesh, PV; Cohen, AL; Murthy, A; Nair, S; Darcourt, JG; Belcheva, A; Kaklamani, VG; Chang, JCN

Koca, E (corresponding author), Houston Methodist Canc Ctr, Houston, TX 77030 USA.

BREAST CANCER RESEARCH AND TREATMENT, 2021; 188 (2): 433

Abstract

Introduction Neoadjuvant endocrine therapy is often utilized to downstage Estrogen Receptor-positive (ER+) breast cancer prior to surgery. However, th......

Full Text Link